Aviv Biomedical Awarded a Phase II SBIR

Aviv Biomedical Inc. has been awarded a Phase II Small Business Innovation Research Grant (SBIR) for a Point of Care System for Determination of Bilirubin Binding Capacity in Neonates.

Public Health Relevance:

Kernicterus is a preventable brain injury in neonates; it is re-emerging in the USA.1 Present day methods of assaying bilirubin do not take into account a child’s ability to safely sequester bilirubin and must be interpreted in terms of gestational age, age, weight and other factors.2 The proposed instrument called, Hematofluorometer, directly measures bilirubin binding and reserve bilirubin binding capacity. It has the potential to be faster, less expensive, and available at the point of care.


References:

1 “Research on Prevention of Bilirubin-Induced Brain Injury and Kernicterus: National Institute of Child Health and Human Development Conference Executive Summary” (2004) LR Blackmon, AA Fanaroff, TNK Raju, Pediatrics V 114, pp. 229-233

2 “Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants” (2010) W Oh, DK Stevenson, JE Tyson, BH Morris, CE Ahlfors, G Jesse Bender, RJ Wong, R Perritt, BR Vohr, KP Van Meurs, HJ Vreman, A Das, DL Phelps,  O’Shea, T Michael, RD Higgins, On Behalf of the NICHD Neonatal Research Network Bethesda MD,
Acta Paediatrica V 99, pp. 673-678

Research reported in this press release is supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number R44EB015924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.